What CJC-1295 actually costs in the US

Start with the honest answer: there is no legitimate retail or pharmacy price for CJC-1295 in the United States, because the Food and Drug Administration has never approved it as a human medicine. A DailyMed search returns no prescription label for it, only a bulk ingredient listing for animal-drug compounding^[1]. So every dollar figure you find online is a grey-market research-chemical price, not a price for an approved drug, and the gap between those two things is the whole story of what CJC-1295 actually costs.

Why there is no pharmacy price

A pharmacy price exists when a medicine is approved and stocked, or when a licensed compounding pharmacy is allowed to prepare it from an approved bulk substance. CJC-1295 fails on both counts. No branded or generic product carries an FDA approval, so no pharmacy dispenses it against a normal prescription, and insurance does not reimburse a drug that has no approved indication.

The compounding route is closed as well. In September 2023 the FDA placed CJC-1295 in Category 2 of its interim 503A bulk drug substances list, the bin reserved for substances that raise significant safety concerns and that the agency does not intend to allow in compounding^[2]. The concerns it cited were immunogenicity (the risk that an injected peptide provokes an immune response), impurities, and the thin base of human clinical data. The classification has been litigated by compounding groups and is still contested into 2026, but the practical position has not changed: a US pharmacy cannot legally compound CJC-1295 for you, so there is no compounded price either. That designation is what tightened the wellness-clinic and telehealth channel that had promoted CJC-1295, often bundled with ipamorelin, in the years before 2023.

It helps to see what an approval-backed price looks like, because a close relative of CJC-1295 has one. Tesamorelin is a growth-hormone-releasing-hormone analogue from the same drug family, and it is FDA-approved and sold in the US as Egrifta for HIV-associated lipodystrophy. It has a real pharmacy price, a real prescribing label, and, for approved patients, a real insurance pathway. That is what an approval buys. CJC-1295 sits one step across a line that matters: same molecular class, no approval, and therefore none of that pricing structure.

That leaves one market, and it is the informal one. Vials labelled CJC-1295 are sold online as research chemicals marked not for human use. That label is not a technicality that clever buyers work around. It is the reason the price is what it is.

What the online price actually buys

Research-chemical CJC-1295 is cheap relative to any licensed injectable medicine, and the low number is the risk signal rather than a bargain. A pharmaceutical product carries the cost of an approved manufacturing process, batch testing, sterility assurance, and a supply chain a regulator can inspect. A research-chemical vial carries none of that guaranteed. You are not paying a lower price for the same thing. You are paying a lower price because it is not the same thing.

There is a second problem that the price tag hides. The name CJC-1295 is attached to two different molecules. The compound studied in the original ConjuChem trials is CJC-1295 with DAC, a modified analogue of growth-hormone-releasing hormone that binds plasma albumin and carries a half-life of 5.8 to 8.1 days in healthy adults^[3]. Most vials sold online as CJC-1295 are the version without DAC, identical to MOD-GRF(1-29), a shorter peptide with a half-life closer to half an hour. The two are priced and marketed as if they were interchangeable. They are not. A buyer comparing prices across vendors is often comparing quotes for two different peptides without knowing it.

So the cheap number online is doing a lot of quiet work. It reflects a product with no approval behind it, no guaranteed identity or purity, and a real chance that the contents are not even the molecule described in the studies people cite when they talk about CJC-1295. A price that low is information, and the information is caution.

How the grey-market price is built

Because there is no reference price, the online figure moves with a handful of vendor-side variables rather than any medical standard. The first is vial size. A vendor selling a 5 mg vial and one selling a 10 mg vial are quoting different quantities, so a headline price means little until you look at cost per milligram. The second is the claimed purity, usually stated as a percentage on the product page with no independent verification attached. The third is whether the vendor publishes any third-party mass-spectrometry testing at all, which most do not. A cheaper vial with no test data and a more expensive vial with a certificate are not the same purchase, even when the label reads the same.

Bundling muddies the comparison further. Many listings sell CJC-1295 together with ipamorelin as a combined kit, and the blended price makes a per-molecule comparison harder still. None of these variables map onto the thing a buyer actually wants to know, which is whether the vial contains what it says at the strength it claims. On the informal market, that question has no reliable answer at any price.

The costs that never appear on the invoice

The sticker price is only part of what CJC-1295 costs an American buyer. The safety base is genuinely thin. The human evidence is concentrated in two small early-phase studies in healthy adults, with no completed efficacy trial and no long-term safety dataset, so the buyer absorbs an unknown that a clinician cannot fully quantify. There is also no recourse: an unapproved product bought outside the medical system comes with no pharmacist to catch an interaction and no manufacturer accountable for a mislabelled vial.

For anyone who competes in sport, there is a separate and much larger bill. CJC-1295 is named directly in section S2.2.4 of the World Anti-Doping Agency Prohibited List as a growth-hormone-releasing-hormone analogue, prohibited at all times, in and out of competition^[4]. A positive test does not cost a vial price. It can cost a season or a career. That is a cost no vendor quotes.

We do not publish grey-market vendor prices or vendor links on this page, and that is a deliberate editorial choice on a safety topic. Listing a lowest price would turn a cost explainer into a shopping page for an unapproved drug, which is not what we do. What a reader needs from a pricing question here is not a cheapest-vendor table. It is an accurate picture of why the cheap number exists and what it leaves out.

What this is not, and where it lands

This is not a buying guide, and none of the above is a recommendation to obtain CJC-1295. If you are weighing any growth-hormone-axis peptide, that decision belongs with a clinician who knows your history and can weigh the evidence against your situation. For the full regulatory picture, see CJC-1295 in the United States and the US regulation hub, and for the pharmacology behind the name confusion, the CJC-1295 peptide page.

The one-line takeaway is simple. There is no approved US price for CJC-1295 because there is no approved US product. The prices that exist are grey-market prices for something that may not be what it claims to be, and the real cost is measured in the unknowns that come with buying an unapproved drug rather than in the number on a checkout page.